

**Boehringer
Ingelheim****Telefax**

APR 5 2005

To: USPTO, Examiner Nita M. Minnifield
Crystal Mall 1, Group 1600
Fax (703) 872-9306
Phone (571) 272-0860

Boehringer Ingelheim
Corporation

Page 1 of 33

April 5, 2005

RE: Reply with Amendment

Application of: Polyakov, I. *et al.*
Art Unit: 1645
Serial No.: 10/828,790
Examiner: Nita M. Minnifield
Conf. No.: 5045
Filed: April 21, 2004
For: Dermatomycosis Vaccine
Docket No.: 3/400-5-C5

Susan K. Pocchiarri, Ph.D.
Admitted in NY and Registered
before the USPTO
Telephone (203) 798-5648
Telefax (203) 798-4408
E-Mail
spocchia@rdg.boehringer-
ingelheim.com
900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368

Dear Sir:

Please find transmitted herewith: (1) a Certificate of Transmission (1 page), (2) a Petition for Extension of Time for three months, in triplicate (3 pages), (3) a Reply with Amendment Under 37 C.F.R. §1.111 (13 pages); and (4) a Declaration of Dr. Igor Polyakov, with attachment (16 pages).

The Commissioner is hereby authorized to charge or credit any fee which may be required to Deposit Account No. 02-2955.

Respectfully submitted,

Susan K. Pocchiarri
Reg. No. 45, 016

Certificate of Transmission under 37 CFR §1.8
I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent and
Trademark Office on April 5, 2005

By: Susan K. Pocchiarri
Reg. No. 45,016

BEST AVAILABLE COPY

Docket No. 3/400-S-C5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Polyakov, I. et al)	Art Unit:	1645
Serial No.:	10/828,790)	Examiner:	Minnifield, N.
Filed:	April 21, 2004)	Confirmation No.:	5045
Docket No.:	3/400-S-C5			
Title:	DERMATOMYCOSES VACCINE			

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY WITH AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

Please enter the amendments and consider the remarks below before commencing examination of the above-captioned application. Applicants submit concurrently herewith: (1) a Petition for Extension of Time for three (3) months up to and including April 5, 2005, accompanied by the necessary fee and (2) a Declaration of Dr. Igor Polyakov under 37 C.F.R. §1.132, with attachment.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 6 of this paper.

BEST AVAILABLE COPY